Pulling SEC filings + quote and writing the call…

Tilray Brands, Inc.
Next earnings Jul 27, 2026 (after close) · consensus $-0.01 EPS, $251M rev
Last earnings -5.1% on 2026-04-01
Chronically unprofitable cannabis-beverage roll-up burning cash and diluting holders ~31%/yr at a rich 6.2x sales — not investable.
Net income -$2.19B · FY2025
Tilray is a serial money-loser dressed up as a 'global lifestyle consumer products company.' Five straight years of net losses culminate in a staggering -$2.19B FY2025 loss on just $821M of revenue — a -266% net margin and a -278% operating margin. Even stripping out what are almost certainly large non-cash goodwill/intangible impairments (the balance sheet shows total assets collapsing -50.9% YoY and equity -56.1%), the underlying engine doesn't work: gross margin is a thin 29.3% for what is increasingly a beer, spirits, and brew-pub business, and operating cash flow swung to -$94.6M. The retained-earnings deficit of -$4.85B is the cumulative scoreboard of a decade of value destruction.
The MD&A reads as strategy-by-acquisition and slogans — 'nexus of cannabis, beverage, wellness, and entertainment,' 16 brew pubs, Craft Acquisitions I and II, HD-D9 seltzers, Liquid Love water. Revenue grew only +4.1% despite bolting on acquired craft-beer volume, which implies the legacy/organic base is flat-to-shrinking. Management touts being 'relentlessly focused on managing our cost structure' while R&D was gutted -55.3% to a token $284K and the company leans on non-GAAP measures ('more fully described below under Use of Non-GAAP Measures') to frame performance — a tell that GAAP results are ugly.
Is TLRY a buy? The one-page verdict, explained →
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $513M | $628M | $627M | $789M | $821M |
| Gross profit | $123M | $117M | $147M | $223M | $241M |
| Operating income | -$132M | -$610M | -$1.37B | -$175M | -$2.28B |
| Net income | -$367M | -$477M | -$1.45B | -$245M | -$2.19B |
| Diluted EPS | -$1.36 | -$0.99 | -$2.35 | -$0.33 | -$2.46 |
| Net margin | -71.6% | -75.9% | -231.6% | -31.1% | -266.3% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Item 3.02: more shares issued in unregistered sale — continued shareholder dilution
Item 3.02: unregistered equity issuance dilutes holders as share count keeps climbing
Item 8.01 other event with exhibits — corporate/strategic update, no P&L impact disclosed
Item 3.02: additional unregistered shares issued — further dilution to equity base
Item 3.02: additional unregistered shares issued — further dilution to equity base
Q3 FY26 (Feb '26): thin ~29% gross margin, ongoing operating losses and cash burn
Q3 FY26 (Feb '26): thin ~29% gross margin, ongoing operating losses and cash burn
Q2 FY26: cannabis/beverage mix stable but losses and dilution persist
Q1 FY26: first quarter post-huge-impairment; revenue flattish, cash draining
Sources: SEC EDGAR (CIK 0001731348, latest 10-Q filed 2026-04-01) · EODHD · Proprietary analysis · as of 7/3/2026, 4:23:22 AM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 12:23 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 1 sale
| 2026-04-21 | Hopkinson David G. Director | Sell | 33.6K @ $6.94 | $233K |
| 2026-01-07 | Cohen Steven Michael Director | Exercise | 12.4K @ $8.99 | $112K |
| 2025-07-31 | SIMON IRWIN D President and CEO | Exercise | 706K @ $0.58 | $410K |
| 2025-07-31 | SIMON IRWIN D President and CEO | Tax | 374K @ $0.58 | $217K |
| 2025-07-31 | Merton Carl A Chief Financial Officer | Exercise | 93.9K @ $0.58 | $54.5K |
| 2025-07-31 | Merton Carl A Chief Financial Officer | Tax | 49.8K @ $0.58 | $28.9K |
| 2025-07-31 | Gendel Mitchell Global General Counsel | Exercise | 93.9K @ $0.58 | $54.5K |
| 2025-07-31 | Gendel Mitchell Global General Counsel | Tax | 49.8K @ $0.58 | $28.9K |
| 2025-07-31 | Gendel Mitchell Global General Counsel | Buy | 6.00K @ $0.58 | $3.50K |
| 2025-07-31 | FALTISCHEK DENISE M Chief Strategy Officer | Exercise | 93.9K @ $0.58 | $54.5K |
| 2025-07-31 | FALTISCHEK DENISE M Chief Strategy Officer | Tax | 49.8K @ $0.58 | $28.9K |
| 2025-07-30 | FALTISCHEK DENISE M Chief Strategy Officer | Exercise | 261K @ $0.61 | $159K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1195 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.